千红制药(002550.SZ)：收到江苏证监局对公司股东出具警示函

Core Viewpoint - The company, Qianhong Biopharmaceutical (002550.SZ), received a warning letter from the Jiangsu Regulatory Bureau of the China Securities Regulatory Commission regarding a violation of disclosure regulations related to shareholding changes [1] Group 1: Regulatory Actions - The warning was issued to Wang Ke for failing to timely disclose an increase in shareholding through a block trade on June 11, 2025, where he acquired 9.6 million shares for a total of 84.096 million yuan [1] - Following this transaction, the combined shareholding of Wang Ke and his concerted action partner, Wang Yaofang, increased from 24.91% to 25.66% [1] - The violation pertains to the failure to disclose the shareholding change when it crossed the 25% threshold, with the required disclosure only made on June 20, 2025 [1] Group 2: Compliance and Recommendations - The regulatory body emphasized the need for Wang Ke to learn from this incident, strengthen knowledge of securities laws, and adhere to information disclosure obligations [1] - Wang Ke is required to submit a written report to the regulatory authority within 10 working days from the receipt of the warning letter [1]